Welcome to our dedicated page for TenX Keane Acquisition SEC filings (Ticker: TENKU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking TenX Keane Acquisition’s shifting trust balances, warrant conversions, and looming redemption deadlines can feel like decoding legal shorthand. A single 8-K about a proposed merger can reshuffle the entire capital structure, yet vital details hide behind jargon. Investors routinely ask, “How do I read TenX Keane Acquisition’s 10-K?” or “Where are TenX Keane Acquisition insider trading Form 4 transactions listed?” The complexity multiplies when extension votes and sponsor contributions appear in supplemental filings. That’s the problem we solve—extracting every material nugget from each page so you don’t spend hours toggling between EDGAR PDFs.
Stock Titan’s AI reviews every document the moment it hits EDGAR, then serves plain-English answers to natural questions like understanding TenX Keane Acquisition SEC documents with AI or “TenX Keane Acquisition 8-K material events explained.” Need a snapshot of unit redemptions inside the latest TenX Keane Acquisition quarterly earnings report 10-Q filing? It’s summarised in seconds. Looking for TenX Keane Acquisition Form 4 insider transactions real-time or tracking TenX Keane Acquisition executive stock transactions Form 4? Alerts arrive as the forms are filed. Our platform also ties each datum back to its source so analysts can verify figures without scrolling through hundreds of pages.
Whether you’re modelling dilution ahead of a definitive merger agreement or comparing sponsor promote disclosures across years, our coverage spans every form: the TenX Keane Acquisition annual report 10-K simplified for trust asset reconciliation, the TenX Keane Acquisition proxy statement executive compensation, and in-depth TenX Keane Acquisition earnings report filing analysis. With AI-powered summaries, red-flag highlights, and real-time updates, you’ll move from raw data to confident decisions faster. No more hunting; find TenX Keane Acquisition SEC filings explained simply, organised logically, and available the moment they become public.
Uber Technologies, Inc. (UBER) filed a Form 4 indicating that director John A. Thain acquired 278 restricted stock units (RSUs) on 07/10/2025 under the company’s RSU Conversion and Deferral Program for Directors. The RSUs were 100% vested at grant and will settle on a one-for-one basis in cash or common stock, at the company’s election, on 07/16/2025. Following the transaction, Thain beneficially owns 278 derivative securities directly. No open-market purchase or sale of Uber common stock occurred, and Table I (non-derivative securities) shows no changes.
Citius Oncology, Inc. (Nasdaq: CTOR) has filed a Form S-1 to raise up to $15 million through a best-efforts offering of common stock, pre-funded warrants and five-year warrants, with Maxim Group acting as exclusive placement agent. The securities will be issued separately but sold together; warrant exercisability hinges on either shareholder approval or pricing conditions that satisfy Nasdaq Rule 5635(d). In addition, Maxim will receive placement-agent warrants equal to 5% of the securities sold.
Use of proceeds: net funds are earmarked primarily for the U.S. commercial launch of LYMPHIR—an engineered IL-2 diphtheria toxin fusion protein approved by the FDA in August 2024 for persistent or recurrent cutaneous T-cell lymphoma (CTCL)—as well as milestone, royalty and license payments, working capital and the repayment of a $3.8 million intercompany note if gross proceeds exceed $10 million.
Liquidity & capital structure: The auditor has issued a going-concern paragraph. Cash and cash equivalents stood at only $112 on 31 March 2025 versus an accumulated deficit of $53.7 million. Outstanding obligations include (i) $16.4 million to suppliers, (ii) $28.4 million under license agreements and (iii) scheduled Eisai payments totalling $13.8 million (principal plus 2% interest) through December 2025. The company recently increased authorised capital to 400 million common shares, leaving substantial capacity for future dilution.
Operational highlights: LYMPHIR targets an estimated $400 million U.S. CTCL market that management believes is underserved. Citius regained Nasdaq bid-price compliance on 26 June 2025 and remains an “emerging growth” and “controlled” company under JOBS Act and Nasdaq rules. The commercial launch is planned for 2H 2025; the company currently records no revenue and relies on Citius Pharma for shared services.
Key risks disclosed: (1) heavy dependence on a single product, (2) substantial near-term cash needs even after the offering, (3) large milestone liabilities to Eisai and Dr. Reddy’s, (4) manufacturing and third-party supply dependence, and (5) potential dilution and market-price volatility.
FAQ
What is the current stock price of TenX Keane Acquisition (TENKU)?
What type of company is TenX Keane Acquisition?
How does TenX Keane Acquisition generate revenue?
What is the primary business model of TENKU?
What role does due diligence play in TENKU's operations?
How is TenX Keane Acquisition positioned in the competitive landscape?
What industries does TenX Keane Acquisition target?
How does TENKU ensure regulatory compliance?
How does TenX Keane Acquisition contribute to market innovation?
